Australia markets closed
  • ALL ORDS

    7,266.30
    +151.80 (+2.13%)
     
  • ASX 200

    6,988.10
    +149.80 (+2.19%)
     
  • AUD/USD

    0.6998
    -0.0035 (-0.50%)
     
  • OIL

    87.29
    +0.68 (+0.79%)
     
  • GOLD

    1,792.30
    -2.70 (-0.15%)
     
  • BTC-AUD

    54,154.29
    +1,929.01 (+3.69%)
     
  • CMC Crypto 200

    863.83
    +21.37 (+2.54%)
     
  • AUD/EUR

    0.6273
    -0.0035 (-0.56%)
     
  • AUD/NZD

    1.0675
    -0.0006 (-0.06%)
     
  • NZX 50

    11,852.15
    -198.17 (-1.64%)
     
  • NASDAQ

    14,454.61
    +451.50 (+3.22%)
     
  • FTSE

    7,466.07
    -88.24 (-1.17%)
     
  • Dow Jones

    34,725.47
    +564.69 (+1.65%)
     
  • DAX

    15,318.95
    -205.32 (-1.32%)
     
  • Hang Seng

    23,550.08
    -256.92 (-1.08%)
     
  • NIKKEI 225

    26,717.34
    +547.04 (+2.09%)
     

iOnctura Presents Positive Clinical Data At ESMO-IO Supporting Advancement of IOA-289, a Novel Autotaxin Inhibitor, Into Phase Ib Pancreatic Cancer Studies

GENEVA, Switzerland, Dec. 09, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, is presenting clinical data confirming the mode of action of its autotaxin inhibitor IOA-289 and showing preclinical evidence of the role of autotaxin inhibition in breaking down tumor resistance mechanisms. IOA-289 will be the first autotaxin inhibitor to be clinically investigated in oncology. The data will be presented as a poster at the European Society of Medical Oncology’s Immuno-Oncology Congress (ESMO-IO) taking place on December 8–11, 2021 as a virtual meeting.

The randomized, double-blind, placebo-controlled study of single ascending doses of IOA-289 showed that IOA-289 lowered circulating levels of LPA in a dose-dependent manner. LPA is a blood-based biomarker of autotaxin inhibition; importantly, LPA levels have been shown to correlate with circulating CA19-9, a clinical biomarker of pancreatic cancer progression, providing a strong rationale for a biomarker-evaluable-response in this study. A Phase I clinical study of IOA-289 in pancreatic cancer, a malignancy typically characterized by a fibrotic and immune excluded phenotype, is in preparation.

Further compelling preclinical data show IOA-289 reduces tumor burden in mouse pancreatic cancer models. The experimental results support the role of cancer-associated fibroblasts (CAFs) in promoting pancreatic adenocarcinoma cells (PDAC) growth. Additionally in preclinical models iOnctura has demonstrated that blocking autotaxin reduces fibrosis and enhances recruitment of T effector cells, two key mechanisms driving tumor mediated resistance to cancer therapy.

The poster presentation at ESMO-IO is entitled “Translating a novel autotaxin inhibitor from preclinical proof of concept in pancreatic cancer to a biomarker response in human subjects” (P131).

The e-poster presentation is available on the ESMO-IO virtual meeting platform and iOnctura’s website.

Contacts

iOnctura
Catherine Pickering
Chief Executive Officer
T : +41 79 952 72 52
E: c.pickering@iOnctura.com

Press Relations
Jeremy Nieckowski
LifeSci Advisors
T: +41 79 699 97 27
E: jnieckowski@lifesciadvisors.com

iOnctura SA is clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface. iOnctura’s best-in-class drug development programs combine immune-mediated and direct anti-tumor activity to deliver molecules with superior clinical efficacy and safety in oncology. Its lead program, IOA-244 is the only semi-allosteric PI3Kdelta specific, orally dosed, small molecule inhibitor that is being developed in solid and hematological malignancies to address tumor and stroma induced immune suppression. IOA-244 is currently in Part B of a Phase 1 study. iOnctura’s second program, IOA-289, is an oral small molecule that inhibits the cross-talk between the tumor and its stroma and is in a Phase 1 clinical study. iOnctura is backed by blue chip investors including M Ventures, Inkef Capital, VI Partners, Schroders Capital, and 3B Future Health Fund. For more information, please visit iOnctura’s website.

IOA-289, originally licensed from Cancer Research UK, is iOnctura’s second clinical compound, a next generation oral small molecule autotaxin inhibitor that is currently being investigated in the healthy volunteer stage of the AION 01 trial (ClinicalTrials.gov Identifier: NCT05027568). A phase 1 clinical study in pancreatic cancer patients is in preparation. iOnctura has undertaken extensive validation of the autotaxin inhibition mechanism in multiple solid tumor preclinical models.

Pancreatic cancer (PDAC): Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer accounting for approximately 90% of cases. PDAC has a poor prognosis, with less than 5% of patients surviving beyond five years after diagnosis. Pancreatic cancer accounts for about 3% of all cancers in the US and about 7% of all cancer deaths, with 60,430 diagnoses each year in the United States and 48,220 deaths.


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting